Cargando…

Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer

A ketogenic diet is expected to be an effective support therapy for patients with cancer, but the degree and duration of carbohydrate restriction are unclear. We performed a case series study of a new ketogenic diet regimen in patients with different types of stage IV cancer. Carbohydrates were rest...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagihara, Keisuke, Kajimoto, Katsufumi, Osaga, Satoshi, Nagai, Naoko, Shimosegawa, Eku, Nakata, Hideyuki, Saito, Hitomi, Nakano, Mai, Takeuchi, Mariko, Kanki, Hideaki, Kagitani-Shimono, Kuriko, Kijima, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284721/
https://www.ncbi.nlm.nih.gov/pubmed/32438645
http://dx.doi.org/10.3390/nu12051473
_version_ 1783544533851570176
author Hagihara, Keisuke
Kajimoto, Katsufumi
Osaga, Satoshi
Nagai, Naoko
Shimosegawa, Eku
Nakata, Hideyuki
Saito, Hitomi
Nakano, Mai
Takeuchi, Mariko
Kanki, Hideaki
Kagitani-Shimono, Kuriko
Kijima, Takashi
author_facet Hagihara, Keisuke
Kajimoto, Katsufumi
Osaga, Satoshi
Nagai, Naoko
Shimosegawa, Eku
Nakata, Hideyuki
Saito, Hitomi
Nakano, Mai
Takeuchi, Mariko
Kanki, Hideaki
Kagitani-Shimono, Kuriko
Kijima, Takashi
author_sort Hagihara, Keisuke
collection PubMed
description A ketogenic diet is expected to be an effective support therapy for patients with cancer, but the degree and duration of carbohydrate restriction are unclear. We performed a case series study of a new ketogenic diet regimen in patients with different types of stage IV cancer. Carbohydrates were restricted to 10 g/day during week one, 20 g/day from week two for three months, and 30 g/day thereafter. A total of 55 patients participated in the study, and data from 37 patients administered the ketogenic diet for three months were analyzed. No severe adverse events associated with the diet were observed. Total ketone bodies increased significantly, and both fasting blood sugar and insulin levels were suppressed significantly for three months after completion of the study. Five patients showed a partial response on Positron emission tomography–computed tomography (PET-CT) at three months. Three and seven patients showed complete and partial responses, respectively at one year. Median survival was 32.2 (maximum: 80.1) months, and the three-year survival rate was 44.5%. After three months on the ketogenic diet, the serum Alb, BS, and CRP (ABC) score could be used to stratify the patients into groups with significantly different survival rates (p < 0.001, log-rank test). Our ketogenic diet regimen is considered to be a promising support therapy for patients with different types of advanced cancer.
format Online
Article
Text
id pubmed-7284721
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72847212020-06-15 Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer Hagihara, Keisuke Kajimoto, Katsufumi Osaga, Satoshi Nagai, Naoko Shimosegawa, Eku Nakata, Hideyuki Saito, Hitomi Nakano, Mai Takeuchi, Mariko Kanki, Hideaki Kagitani-Shimono, Kuriko Kijima, Takashi Nutrients Article A ketogenic diet is expected to be an effective support therapy for patients with cancer, but the degree and duration of carbohydrate restriction are unclear. We performed a case series study of a new ketogenic diet regimen in patients with different types of stage IV cancer. Carbohydrates were restricted to 10 g/day during week one, 20 g/day from week two for three months, and 30 g/day thereafter. A total of 55 patients participated in the study, and data from 37 patients administered the ketogenic diet for three months were analyzed. No severe adverse events associated with the diet were observed. Total ketone bodies increased significantly, and both fasting blood sugar and insulin levels were suppressed significantly for three months after completion of the study. Five patients showed a partial response on Positron emission tomography–computed tomography (PET-CT) at three months. Three and seven patients showed complete and partial responses, respectively at one year. Median survival was 32.2 (maximum: 80.1) months, and the three-year survival rate was 44.5%. After three months on the ketogenic diet, the serum Alb, BS, and CRP (ABC) score could be used to stratify the patients into groups with significantly different survival rates (p < 0.001, log-rank test). Our ketogenic diet regimen is considered to be a promising support therapy for patients with different types of advanced cancer. MDPI 2020-05-19 /pmc/articles/PMC7284721/ /pubmed/32438645 http://dx.doi.org/10.3390/nu12051473 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hagihara, Keisuke
Kajimoto, Katsufumi
Osaga, Satoshi
Nagai, Naoko
Shimosegawa, Eku
Nakata, Hideyuki
Saito, Hitomi
Nakano, Mai
Takeuchi, Mariko
Kanki, Hideaki
Kagitani-Shimono, Kuriko
Kijima, Takashi
Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
title Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
title_full Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
title_fullStr Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
title_full_unstemmed Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
title_short Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer
title_sort promising effect of a new ketogenic diet regimen in patients with advanced cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284721/
https://www.ncbi.nlm.nih.gov/pubmed/32438645
http://dx.doi.org/10.3390/nu12051473
work_keys_str_mv AT hagiharakeisuke promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT kajimotokatsufumi promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT osagasatoshi promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT nagainaoko promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT shimosegawaeku promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT nakatahideyuki promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT saitohitomi promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT nakanomai promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT takeuchimariko promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT kankihideaki promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT kagitanishimonokuriko promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer
AT kijimatakashi promisingeffectofanewketogenicdietregimeninpatientswithadvancedcancer